Learn About D-Minus Hemolytic Uremic Syndrome

What is the definition of D-Minus Hemolytic Uremic Syndrome?
D-minus (diarrhea negative) hemolytic uremic syndrome is an extremely rare, progressive genetic disease characterized by low levels of red blood cells (hemolytic anemia), low platelets (thrombocytopenia), and an inability of the kidneys to process waste products from the blood (uremia).
Save information for later
Sign Up
What are the symptoms of D-Minus Hemolytic Uremic Syndrome?
Symptoms of D-minus hemolytic uremic syndrome may include malaise, fatigue, irritability, lethargy, decreased urine, paleness, scattered bruising, gastrointestinal bleeding, high blood pressure, headaches, double vision, facial paralysis, stroke, seizures, coma, fluid in the lungs, enlarged heart, and kidney failure.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for D-Minus Hemolytic Uremic Syndrome?
Treatment for D-minus hemolytic uremic syndrome may include intravenous nutrition and fluid replacement, kidney or peritoneal dialysis, blood transfusion, vasodilators, medications, such as eculizumab and ultomiris (favulizumab-cwyz), plasma exchange (plasmapheresis), immunosuppressive therapy, or kidney transplant.
Who are the top D-Minus Hemolytic Uremic Syndrome Local Doctors?
GA
Gianluigi Ardissino
Elite
Highly rated in
15
conditions

Fondazione IRCCS Ca' Granda Ospedale MAggiore Policlinico, UOC Nefrologia E Dialisi

Milano, IT 

Gianluigi Ardissino practices in Milano, Italy. Ardissino is rated as an Elite expert by MediFind in the treatment of D-Minus Hemolytic Uremic Syndrome. He is also highly rated in 15 other conditions, according to our data. His top areas of expertise are D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, Kidney Transplant, and Bone Marrow Transplant.

CL
Chantal Loirat
Elite
Highly rated in
11
conditions

Hôpital Robert Debré

Service D'hématologie Clinique, 
Paris, FR 

Chantal Loirat practices in Paris, France. Loirat is rated as an Elite expert by MediFind in the treatment of D-Minus Hemolytic Uremic Syndrome. She is also highly rated in 11 other conditions, according to our data. Her top areas of expertise are D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, Kidney Transplant, and Liver Transplant.

 
 
 
 
Learn about our expert tiers
Learn more
CL
Christoph B. Licht
Elite
Highly rated in
18
conditions

William Osler Health System, Brampton Civic Hospital And Peel Memorial Centre For Integrated Health And Wellness

Brampton, ON, CA 

Christoph Licht practices in Brampton, Canada. Licht is rated as an Elite expert by MediFind in the treatment of D-Minus Hemolytic Uremic Syndrome. He is also highly rated in 18 other conditions, according to our data. His top areas of expertise are Hemolytic-Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Kidney Transplant, and Bone Marrow Transplant.

View All Doctors
What are the latest D-Minus Hemolytic Uremic Syndrome Clinical Trials?
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Who is this study for: Patients with Atypical Hemolytic Uremic Syndrome
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Drug
Study Drug: Crovalimab
Study Phase: Phase 3

Summary: This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Who is this study for: Adult and adolescent participants with atypical hemolytic uremic syndrome
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Drug
Study Drug: Crovalimab
Study Phase: Phase 3

Summary: This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.

View All Clinical Trials
What are the Latest Advances for D-Minus Hemolytic Uremic Syndrome?
The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review.
Condition: Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS).
Journal: Pediatric nephrology (Berlin, Germany)
Treatment Used: Eculizumab
Number of Patients: 940
Published: July 21, 2022
The frontline of TMA management.
Condition: Thrombotic Microangiopathy (TMA)
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Treatment Used: Plasma Exchange, Rituximab, Caplacizumab, and Eculizumab,
Number of Patients: 0
Published: June 06, 2022
Tired of the same old research?
Check Latest Advances
Oxaliplatin-induced thrombotic microangiopathy: a case report.
Condition: Metastatic Colon Cancer/Oxaliplatin-Induced Thrombotic Microangiopathy
Journal: Journal of medical case reports
Treatment Used: Oxaliplatin-Based Chemotherapy
Number of Patients: 1
Published: March 19, 2022
View All Latest Advances